RPD Stock Overview
Operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Royalty Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.77 |
| 52 Week High | US$26.21 |
| 52 Week Low | US$23.35 |
| Beta | 0.47 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -34.82% |
| 5 Year Change | n/a |
| Change since IPO | -37.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| RPD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -7.0% | -0.4% |
| 1Y | n/a | -21.6% | 7.1% |
Return vs Industry: Insufficient data to determine how RPD performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RPD performed against the German Market.
Price Volatility
| RPD volatility | |
|---|---|
| RPD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RPD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine RPD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Royalty Pharma plc Fundamentals Summary
| RPD fundamental statistics | |
|---|---|
| Market cap | €14.65b |
| Earnings (TTM) | €1.09b |
| Revenue (TTM) | €2.15b |
10.2x
P/E Ratio5.1x
P/S RatioIs RPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPD income statement (TTM) | |
|---|---|
| Revenue | US$2.27b |
| Cost of Revenue | US$491.91m |
| Gross Profit | US$1.77b |
| Other Expenses | US$628.98m |
| Earnings | US$1.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.58 |
| Gross Margin | 78.29% |
| Net Profit Margin | 50.53% |
| Debt/Equity Ratio | 74.2% |
How did RPD perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield32%
Payout RatioDoes RPD pay a reliable dividends?
See RPD dividend history and benchmarks| Royalty Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Nov 15 2024 |
| Dividend Pay Date | Dec 10 2024 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 18 days |
Does RPD pay a reliable dividends?
See RPD dividend history and benchmarks